Glioblastoma Multiforme in the over 70's: “To treat or not to treat with radiotherapy?”

Abstract Background The incidence of Glioblastoma Multiforme (GBM) is increasing among the older population and is associated with poor prognosis. Management guidelines are lacking in this group. The purpose of this study was to analyze survival data and determine predictors of survival in patients...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Cancer Medicine
المؤلفون الرئيسيون:	Aisling M. Glynn, Guhan Rangaswamy, Julianne O'Shea, Mary Dunne, Roger Grogan, Stephen MacNally, David Fitzpatrick, Clare Faul
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Wiley 2019-08-01
الموضوعات:	age debulking Glioblastoma performance status radiotherapy Temozolomide
الوصول للمادة أونلاين:	https://doi.org/10.1002/cam4.2398

مواد مشابهة

Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide
حسب: Lu-Ting Kuo, وآخرون
منشور في: (2017-01-01)

Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors
حسب: Supriya Mallick, وآخرون
منشور في: (2015-01-01)

Synergistic Effects of Temozolomide and Doxorubicin in the Treatment of Glioblastoma Multiforme: Enhancing Efficacy through Combination Therapy
حسب: Laxmi Dhungel, وآخرون
منشور في: (2024-02-01)

The Role of Progranulin (PGRN) in the Pathogenesis of Glioblastoma Multiforme
حسب: Łukasz A. Poniatowski, وآخرون
منشور في: (2024-01-01)

De Novo Self-Assembling Peptides Mediate the Conversion of Temozolomide and Delivery of a Model Drug into Glioblastoma Multiforme Cells
حسب: Megan Pitz, وآخرون
منشور في: (2022-09-01)

Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma
حسب: Evrim Metcalfe, وآخرون
منشور في: (2016-08-01)

Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance
حسب: Jianlin Pu, وآخرون
منشور في: (2025-05-01)

Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes
حسب: Marcin Jezierzański, وآخرون
منشور في: (2024-07-01)

Unusual presentation of glioblastoma in the brainstem: a case report of a diffuse pontine glioblastoma multiforme and surgical management
حسب: Brandon Edelbach, وآخرون
منشور في: (2024-03-01)

Gene signatures associated with prognosis and chemotherapy resistance in glioblastoma treated with temozolomide
حسب: Tonia Carter, وآخرون
منشور في: (2023-12-01)

Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients
حسب: Federico Cucchiara, وآخرون
منشور في: (2022-07-01)

Tumor Treating Fields Alter the Kinomic Landscape in Glioblastoma Revealing Therapeutic Vulnerabilities
حسب: Amber B. Jones, وآخرون
منشور في: (2023-08-01)

Glioblastoma in an old patient treated with a combination of tumor-treating fields and standard chemoradiotherapy: A case report
حسب: Yiting Yang, وآخرون
منشور في: (2023-01-01)

Radiotherapy in Glioblastoma Multiforme: Evolution, Limitations, and Molecularly Guided Future
حسب: Castalia Fernández, وآخرون
منشور في: (2025-09-01)

Exploring the role of Nrf2 signaling in glioblastoma multiforme
حسب: Wireko Andrew Awuah, وآخرون
منشور في: (2022-09-01)

Preparation and evaluation of temozolomide loaded PLGA nanoparticles for the treatment of glioblastoma multiforme
حسب: Şule Şahin, وآخرون
منشور في: (2025-10-01)

Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance
حسب: Young Keun Hwang, وآخرون
منشور في: (2024-08-01)

Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
حسب: Karoline Almeida Lima, وآخرون
منشور في: (2023-04-01)

Clinical Relevance and Interplay between miRNAs in Influencing Glioblastoma Multiforme Prognosis
حسب: Samantha Epistolio, وآخرون
منشور في: (2024-02-01)

p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme
حسب: Jiao Meng, وآخرون
منشور في: (2024-03-01)

A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches
حسب: Meijun Liu, وآخرون
منشور في: (2025-06-01)

IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment
حسب: Gilbert Aaron Lee, وآخرون
منشور في: (2025-03-01)

Molecular Docking and Molecular Dynamics Studies Reveal Secretory Proteins as Novel Targets of Temozolomide in Glioblastoma Multiforme
حسب: Sumera, وآخرون
منشور في: (2022-10-01)

Development of Angiopep-2 targeted dendrimer-based nanotheranostic system for enhanced temozolomide delivery to glioblastoma multiforme
حسب: Ashish Kumar Parashar, وآخرون
منشور في: (2025-02-01)

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
حسب: Ehsan Alimohammadi, وآخرون
منشور في: (2020-02-01)

Nanotechnology-based cancer chemoprevention in glioblastoma
حسب: Aima Adylova, وآخرون
منشور في: (2023-05-01)

Comparison of multi-cycle and standard-cycle temozolomide chemotherapies in patients with glioblastoma undergoing surgery and successive radiotherapy
حسب: Yuan Fu, وآخرون
منشور في: (2023-06-01)

Efficacy of D,L-methadone in the treatment of glioblastoma in vitro
حسب: Konstantin Brawanski, وآخرون
منشور في: (2018-07-01)

Current chemotherapy strategies for adults with IDH-wildtype glioblastoma
حسب: Jing Bao, وآخرون
منشور في: (2024-07-01)

Survival and recurrence patterns of multifocal glioblastoma after radiation therapy
حسب: Syed M, وآخرون
منشور في: (2018-10-01)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
حسب: Yu-Ling Tsai, وآخرون
منشور في: (2020-09-01)

Comparative proteogenomic characterization of glioblastoma
حسب: Samia Asif, وآخرون
منشور في: (2019-06-01)

Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy
حسب: Shigeo Ohba, وآخرون
منشور في: (2025-01-01)

TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
حسب: Jian Yu, وآخرون
منشور في: (2022-07-01)

Factors Affecting Outcome in the Treatment of Glioblastoma
حسب: Nenad Koruga, وآخرون
منشور في: (2021-01-01)

Glioblastoma Multiforme: Probing Solutions to Systemic Toxicity towards High-Dose Chemotherapy and Inflammatory Influence in Resistance against Temozolomide
حسب: Sadia Nasir, وآخرون
منشور في: (2023-02-01)

Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized trials
حسب: Yuanyuan Chen, وآخرون
منشور في: (2025-02-01)

Delta-radiomics Entropy Based on Tumor Heterogeneity Concept – Response Predictor to Irradiation for Unresectable/recurrent Glioblastoma
حسب: Camil Ciprian MIRESTEAN, وآخرون
منشور في: (2022-12-01)

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
حسب: Combs Stephanie E, وآخرون
منشور في: (2011-09-01)

Treatment of glioblastoma in Greenlandic patients
حسب: Simone Frandsen, وآخرون
منشور في: (2023-12-01)